Effect of transporter and DNA repair gene polymorphisms to lung cancer chemotherapy toxicity

Juan Chen(Chinese Academy of Sciences), Zhaoqian Liu(Central South University), Huihua Li(Central South University), Chuntian Li(Shenyang 242 Hospital), Hong‐Hao Zhou(New York University), Ting Zou, Lin Wu(Materials Systems (United States)), Ying Wang(Central South University), Xiangping Li(Central South University), Chenyue Qian(Central South University), Ji‐Ye Yin(Central South University), Zhan Wang(Qinghai University), Wei Zhang(Central South University)

Tumor Biology

September 11, 2015

10.1007/s13277-015-4048-0

Cited by 20

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|677

Aristolochic acid and the etiology of endemic (Balkan) nephropathy

|Proceedings of the National Academy of Sciences|2007|598

Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

|Clinical Cancer Research|2015|469

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|390

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2013|246